Yervoy is a prescription medication used to treat certain types of cancer, including melanoma. According to the first source [1], Yervoy is a biologic drug, which means it is made from living cells and is more complex than traditional chemical drugs. The patent for Yervoy expired in 2022, which means that generic versions of the drug may become available in the future.

The second source [2] provides information about financial assistance programs for patients who need help paying for Yervoy. Bristol-Myers Squibb, the manufacturer of Yervoy, offers several programs to help eligible patients afford their medication. These programs include co-pay assistance, which can reduce the out-of-pocket cost for Yervoy, and a patient assistance program, which provides free medication to eligible patients who do not have insurance or who cannot afford their medication.

The third source [3] mentions that discounts were used to persuade the National Institute for Health and Care Excellence (NICE) to recommend Yervoy for use in the UK's National Health Service (NHS). The discounts were negotiated between Bristol-Myers Squibb and the NHS, and they helped to make Yervoy more affordable for patients who needed it.

In summary, patients who need help paying for Yervoy may be eligible for financial assistance programs offered by Bristol-Myers Squibb. Additionally, discounts have been used in the past to make Yervoy more affordable for patients in the UK. It is important to consult with a healthcare provider to determine if Yervoy is the right treatment option and to explore all available options for financial assistance.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/YERVOY
[2] https://www.bmsaccesssupport.bmscustomerconnect.com/patient/financial-support
[3] http://www.pmlive.com/pharma_news/discounts_persuade_nice_to_recommend_skin_cancer_drugs_yervoy_and_zelboraf_445335